Guardant Health, Inc. (GH)

25.80 -0.46 (-1.75%) At close: 04:00PM EDT

Guardant Health, Inc.

3100 Hanover Street
Palo Alto, CA 94304
United States
855 698 8887
https://guardanthealth.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 1,793

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Helmy Eltoukhy Ph.D.	Co-Founder, Co-CEO & Chairman	11.63k	N/A	1979
Dr. AmirAli Talasaz Ph.D.	Co-CEO & Director	11.18k	N/A	1979
Mr. Michael Bell	Chief Financial Officer	630.99k	N/A	1969
Mr. John G. Saia	Chief Legal Officer & Corp. Sec.	627.18k	N/A	1973
Dr. Craig Eagle M.D.	Chief Medical Officer	649.13k	N/A	1967
Mr. Christopher Freeman	Chief Commercial Officer	630.39k	N/A	1974
Ms. Ines Dahne-Steuber	Chief Operating Officer	N/A	N/A	N/A
Ms. Darya Chudova	Chief Technology Officer	N/A	N/A	N/A
Mr. Kumud Kalia	Chief Information Officer	N/A	N/A	1966
Ms. Jennifer Higgins	VP of Public Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Corporate governance

Guardant Health, Inc.’s ISS governance QualityScore as of 1 September 2023 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.